Context Therapeutics amends BioAtla license deal for CT-202 drug
Go back to Context Therapeutics amends BioAtla license deal for CT-202 drug| (NASDAQ: BCAB) | Delayed: 3.12 -0.14 (4.29%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.26 | 52 Week High | $ | |||
| Open | $3.35 | 52 Week Low | $ | |||
| Day High | $3.37 | P/E | N/A | |||
| Day Low | $3.06 | EPS | $ | |||
| Volume | 21,457 | |||||
| (NASDAQ: CNTX) | Delayed: 0.42 -0.02 (4.55%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.44 | 52 Week High | $ | |||
| Open | $0.43 | 52 Week Low | $ | |||
| Day High | $0.44 | P/E | N/A | |||
| Day Low | $0.42 | EPS | $ | |||
| Volume | 1,029,578 | |||||
